BRPI0608185A2 - processo para redução do tamanho de partìcula de aripiprazol - Google Patents

processo para redução do tamanho de partìcula de aripiprazol

Info

Publication number
BRPI0608185A2
BRPI0608185A2 BRPI0608185-1A BRPI0608185A BRPI0608185A2 BR PI0608185 A2 BRPI0608185 A2 BR PI0608185A2 BR PI0608185 A BRPI0608185 A BR PI0608185A BR PI0608185 A2 BRPI0608185 A2 BR PI0608185A2
Authority
BR
Brazil
Prior art keywords
particle size
reducing
aripiprazole
aripiprazole particle
micronized
Prior art date
Application number
BRPI0608185-1A
Other languages
English (en)
Inventor
Guy Samburshi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI0608185A2 publication Critical patent/BRPI0608185A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Quinoline Compounds (AREA)

Abstract

PROCESSOS PARA REDUçãO DO TAMANHO DE PARTìCULA DE ARIPIPRAZOL. Forma II de aripiprazol micronizado que tem um formato de partícula e é caracterizada por 90% ou mais das partículas terem um tamanho de partícula de aproximadamente 30 pim, e a Forma II de aripiprazol micronizado não ter mais de 10% por peso de aripiprazol do Tipo C, conforme determinado pela difração de raios X e processos para sua obtenção.
BRPI0608185-1A 2005-12-22 2006-12-22 processo para redução do tamanho de partìcula de aripiprazol BRPI0608185A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75346605P 2005-12-22 2005-12-22
PCT/US2006/048761 WO2007075871A2 (en) 2005-12-22 2006-12-22 Processes for reducing particle size of aripiprazole

Publications (1)

Publication Number Publication Date
BRPI0608185A2 true BRPI0608185A2 (pt) 2009-11-17

Family

ID=38218601

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608185-1A BRPI0608185A2 (pt) 2005-12-22 2006-12-22 processo para redução do tamanho de partìcula de aripiprazol

Country Status (7)

Country Link
US (1) US20070272777A1 (pt)
EP (1) EP1919453A2 (pt)
JP (1) JP2008537540A (pt)
BR (1) BRPI0608185A2 (pt)
IL (1) IL191286A0 (pt)
TW (1) TW200800202A (pt)
WO (1) WO2007075871A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2550726A1 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
ATE429906T1 (de) * 2006-01-05 2009-05-15 Teva Pharma Trockene aripiprazolformulierungen
ES2318693T5 (es) * 2006-01-05 2018-10-04 Teva Pharmaceutical Industries Ltd Procedimiento de granulación en húmedo para la preparación de composiciones farmacéuticas de aripiprazol
KR101408370B1 (ko) * 2012-06-26 2014-06-18 주식회사지씨비 아리피프라졸-유기산 공결정을 함유하는 제제 및 이의 제조 방법
AR096131A1 (es) 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
EP2838513B1 (en) * 2013-04-30 2017-04-05 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
CN105924393A (zh) * 2016-07-05 2016-09-07 陕西省食品药品检验所 一种阿立哌唑新晶型及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE69112917T2 (de) * 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
US6221153B1 (en) * 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
WO2001070697A1 (en) * 2000-03-20 2001-09-27 Teva Pharmaceutical Industries Ltd. Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and n-(4-methoxyphenyl)-3-chloropropionamide
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE60302139T3 (de) * 2003-01-09 2011-02-24 Otsuka Pharmaceutical Co., Ltd. Verfahren zur herstellung von aripiprazole
AU2003230192A1 (en) * 2003-03-21 2004-10-11 Hetero Drugs Limited Novel crystalline forms of aripiprazole
WO2004106322A2 (en) * 2003-04-25 2004-12-09 Cadila Healthcare Limited Polymorphs of aripiprazole
US7456181B2 (en) * 2003-07-25 2008-11-25 Hetero Drugs Limited Aripiprazole crystalline forms
US7166418B2 (en) * 2003-09-03 2007-01-23 Matsushita Electric Industrial Co., Ltd. Sulfonamide compound, polymer compound, resist material and pattern formation method
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
CA2550726A1 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
EP1765782A1 (en) * 2004-02-05 2007-03-28 Teva Pharmaceutical Industries Ltd Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril
US20050277650A1 (en) * 2004-04-20 2005-12-15 Sundaram Venkataraman Process for preparing aripirazole hydrate
DE102005048695A1 (de) * 2004-10-12 2006-05-18 Chemagis Ltd. Verfahren zur Herstellung und Reinigung von Carbostyrilverbindungen wie beispielsweise Aripiprazol und 7-(4-Halobutoxy)-3,4-dihydro-2(1H)-quinolinonen
US20060079690A1 (en) * 2004-10-12 2006-04-13 Vladimir Naddaka Processes for preparing 7-hydroxy-3,4-dihydro-2(1H)-quinolinone and the use in aripiprazole preparation thereof
ES2526415T3 (es) * 2005-03-17 2015-01-12 Synthon B.V. Comprimidos farmacéuticos de aripiprazol cristalino de tipo II
WO2006097343A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Process of making crystalline type ii aripiprazole

Also Published As

Publication number Publication date
JP2008537540A (ja) 2008-09-18
WO2007075871A9 (en) 2007-08-16
WO2007075871A2 (en) 2007-07-05
WO2007075871A3 (en) 2008-04-03
TW200800202A (en) 2008-01-01
IL191286A0 (en) 2009-08-03
US20070272777A1 (en) 2007-11-29
EP1919453A2 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
BRPI0608185A2 (pt) processo para redução do tamanho de partìcula de aripiprazol
PH12018501226A1 (en) Methods for treating huntingtons disease
MX2014012556A (es) Nanotubos de carbono que tienen una distribucion de tamaño bimodal.
BRPI0818911A8 (pt) composição, processo para a preparação de bronze de hidrogênio e tungstênio ou de uma composição de bronze de hidrogênio e tungstênio, dispersão de partícula, e, uso de partículas de bronze de hidrogênio e tungstênio ou de partículas que contenham bronze de hidrogênio e tungstênio
BR112014032152A2 (pt) partículas abrasivas tendo formatos particulares e métodos para formar tais partículas
MY181036A (en) Graphene composite and method of producing the same
BR112014033004A2 (pt) oligonucleotídeo para tratamento de pacientes com distrofia muscular
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
MY161818A (en) Styrenyl derivate compounds for treating ophthalmic diseases and disorders
BR112017015008A2 (pt) trilho
BR112017002926A2 (pt) composições e método para aprimorar o perfil de liberação farmacocinético inicial in vivo
WO2010059913A3 (en) Preparation of rasagiline and salts thereof
BR112014009097A2 (pt) composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
BR112014013923A2 (pt) método para produção de mulita percolada num corpo de material, mulita percolada, uso da mulita percolada e corpo de material
BR112014031048A2 (pt) composições para controle de artrópodes nocivos e método para controle de artrópodes nocivos
BR112015017846A2 (pt) aperitivos que contêm fruta e fabricação dos mesmos
BR112015017843A2 (pt) composição de fertilizante e método para colocar em suspensão o fertilizante em uma solução aquosa
BR112018008873A8 (pt) chapa de aço laminada a quente de alta resistência e método de fabricação da mesma
BR112018077220A2 (pt) partículas núcleo-invólucro, material de enchimento escoável, método para produzir partículas núcleo-invólucro ou material de enchimento escoável, composição moldável para produzir alimentadores, alimentador e uso de partículas núcleo-invólucro ou material de enchimento escoável
BR112015032485A8 (pt) artigo para fumar, filtro para um artigo para fumar e uso do mesmo
BR112015020061A2 (pt) tratamento de câncer à base de estratificação de caix
JP2018532834A5 (pt)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2211 DE 21/05/2013.